InfuSystem Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InfuSystem in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" InfuSystem stock.
View analyst ratings for InfuSystem or view top-rated stocks.

Wall Street analysts have given InfuSystem a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InfuSystem wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

InfuSystem saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 186,200 shares, a decrease of 35.6% from the March 31st total of 289,100 shares. Based on an average trading volume of 106,700 shares, the days-to-cover ratio is currently 1.7 days. Currently, 1.0% of the shares of the company are sold short.
View InfuSystem's Short Interest.

InfuSystem is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for InfuSystem.

InfuSystem Holdings Inc. (NYSEAMERICAN:INFU) issued its earnings results on Thursday, May, 6th. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.01. InfuSystem had a net margin of 7.91% and a trailing twelve-month return on equity of 29.88%.
View InfuSystem's earnings history.

InfuSystem issued an update on its FY 2021 earnings guidance on Thursday, May, 13th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $107 million-$110 million, compared to the consensus revenue estimate of $108.97 million.

4 brokerages have issued 1 year price targets for InfuSystem's shares. Their forecasts range from $17.00 to $28.00. On average, they expect InfuSystem's stock price to reach $24.50 in the next twelve months. This suggests a possible upside of 32.1% from the stock's current price.
View analysts' price targets for InfuSystem or view top-rated stocks among Wall Street analysts.

Some companies that are related to InfuSystem include Alphatec (ATEC), Cardiovascular Systems (CSII), Pulmonx (LUNG), Inovio Pharmaceuticals (INO), CryoLife (CRY), Atrion (ATRI), OrthoPediatrics (KIDS), MiMedx Group (MDXG), Tactile Systems Technology (TCMD), SI-BONE (SIBN), LeMaitre Vascular (LMAT), Cerus (CERS), AngioDynamics (ANGO), Orthofix Medical (OFIX) and Surmodics (SRDX).
View all of INFU's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InfuSystem investors own include Macquarie Infrastructure (MIC), Ampio Pharmaceuticals (AMPE), Second Sight Medical Products (EYES), Navidea Biopharmaceuticals (NAVB), Otelco (OTEL), Pershing Gold (PGLC), Palatin Technologies (PTN), AgroFresh Solutions (AGFS), Advanced Micro Devices (AMD) and Digital Turbine (APPS).

InfuSystem trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "INFU."

InfuSystem's stock is owned by a number of retail and institutional investors. Top institutional investors include Minerva Advisors LLC (4.38%), BlackRock Inc. (3.99%), Russell Investments Group Ltd. (3.26%), Renaissance Technologies LLC (2.63%), Geode Capital Management LLC (1.25%) and White Pine Capital LLC (0.77%). Company insiders that own InfuSystem stock include Awm Investment Company, Inc, Barry G Steele, Blueline Capital Partners Ii,, Carrie Lachance, Christopher R Sansone, Gregg Owen Lehman, Jeannine Sheehan, Meridian Ohc Partners, Lp, Paul Andrew Gendron, Richard Dilorio, Scott Shuda and Thomas Mark Ruiz.
View institutional ownership trends for InfuSystem.

INFU stock was sold by a variety of institutional investors in the last quarter, including Minerva Advisors LLC, Wedge Capital Management L L P NC, EAM Investors LLC, Renaissance Technologies LLC, EAM Global Investors LLC, Northern Trust Corp, White Pine Capital LLC, and Bank of New York Mellon Corp. Company insiders that have sold InfuSystem company stock in the last year include Blueline Capital Partners Ii,, Gregg Owen Lehman, Meridian Ohc Partners, Lp, Richard Dilorio, and Thomas Mark Ruiz.
View insider buying and selling activity for InfuSystem or view top insider-selling stocks.

INFU stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Calamos Advisors LLC, Acuitas Investments LLC, Sowell Financial Services LLC, Geode Capital Management LLC, Millrace Asset Group Inc., Acadian Asset Management LLC, and Russell Investments Group Ltd.. Company insiders that have bought InfuSystem stock in the last two years include Awm Investment Company, Inc, Barry G Steele, Carrie Lachance, Christopher R Sansone, Jeannine Sheehan, Paul Andrew Gendron, Richard Dilorio, and Scott Shuda.
View insider buying and selling activity for InfuSystem or or view top insider-buying stocks.

Shares of INFU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INFU stock can currently be purchased for approximately $18.54.

InfuSystem has a market capitalization of $379.50 million and generates $81.11 million in revenue each year.

InfuSystem employs 282 workers across the globe.

The official website for InfuSystem is ir.infusystem.com.

InfuSystem is headquartered at 31700 Research Park Dr, MADISON HEIGHTS, MI 48071-4627, United States.

InfuSystem's mailing address is 31700 Research Park Dr, MADISON HEIGHTS, MI 48071-4627, United States. The medical instruments supplier can be reached via phone at +1-248-2911210.